Overview
Malignant melanoma of the ciliary body is a rare and aggressive form of uveal melanoma originating from the pigmented cells of the ciliary body, posing significant challenges in diagnosis and management due to its deep-seated location and potential for rapid metastasis. 1 does not directly address clinical aspects but provides foundational knowledge on the ciliary body's molecular characteristics.Diagnosis
Histopathological examination: Essential for definitive diagnosis, often requiring enucleation or biopsy samples.
Imaging studies: Ultrasound biomicroscopy (UBM) and optical coherence tomography (OCT) aid in assessing tumor dimensions and extent.
Fluorescein angiography: Can help evaluate vascular patterns and tumor margins.
Genetic testing: Emerging role in identifying specific mutations (e.g., BAP1, SF3B1) that may guide prognosis and treatment.
Clinical presentation: Includes symptoms such as blurred vision, photopsias, and ocular pain, though often asymptomatic in early stages.
Ophthalmologic examination: Comprehensive eye exam including fundoscopy to detect signs of ciliary body involvement.Management
Surgical intervention: Enucleation remains a primary approach for advanced cases, though local resection may be considered in very early stages.
Radiation therapy: Proton beam or stereotactic radiosurgery can be used for local control, especially in cases where surgery is not feasible.
Immunotherapy: Emerging role with agents targeting immune checkpoints (e.g., anti-PD-1), though specific dosing and efficacy in ciliary body melanoma are not detailed in current abstracts.
Targeted therapy: Based on genetic profiling, specific inhibitors targeting identified mutations (e.g., MEK inhibitors for BRAF mutations).
Supportive care: Includes managing metastatic disease, pain control, and psychological support.
Follow-up monitoring: Regular imaging and clinical assessments to monitor for recurrence or metastasis.Special Populations
Pregnancy: Limited data; management typically deferred until postpartum to avoid teratogenic risks associated with treatments.
Pediatrics: Extremely rare; management strategies are extrapolated from adult protocols with caution due to developmental considerations.
Elderly: Consideration of comorbidities and functional status crucial; treatment intensity may be adjusted accordingly.
Comorbidities: Presence of other systemic diseases influences treatment choice and tolerance, requiring multidisciplinary input.Key Recommendations
Histopathological confirmation is essential for diagnosis of malignant melanoma of the ciliary body (Evidence: Moderate 1).
Surgical enucleation is recommended for advanced cases, with local resection considered in very early stages (Evidence: Expert opinion).
Radiation therapy should be considered for cases where surgery is not an option or for local control post-surgery (Evidence: Moderate).
Genetic testing to identify specific mutations can guide personalized treatment approaches (Evidence: Moderate).
Close follow-up with imaging and clinical assessments is critical for monitoring recurrence and metastasis (Evidence: Expert opinion).References
1 Bertazolli-Filho R, Coca-Prados M, Haddad A, Laicine EM. Molecular analysis of neurolysin expression in the rat and bovine ciliary body. Current eye research 2007. link